Seattle Children’s began palivizumab (Synagis) administration in mid-October due to increasing respiratory syncytial virus (RSV) rates. Our providers will identify and refer their eligible patients. We ask that community providers with patients who need Synagis provide it directly rather than referring patients to Seattle Children’s due to capacity constraints at the hospital.
The American Academy of Pediatrics (AAP) continues to recommend five monthly doses for eligible patients while recognizing the need for monitoring and flexibility in what might be an atypical season. See the AAP recommendations.
